Rubinstein Wendy S
Evanston Northwestern Healthcare Center for Medical Genetics, Evanston, IL 60201, USA.
Fam Cancer. 2008;7(1):5-14. doi: 10.1007/s10689-007-9148-6. Epub 2007 Jul 12.
Medical geneticists must generate a differential diagnosis, practice evidence-based medicine, and apply ethical, legal, and social issue (ELSI) principles in the clinical setting. Several clinical scenarios are presented which illustrate dilemmas in the cancer genetics setting. These include the differential diagnosis of breast and gastric cancer, and the predicament posed by the need to practice evidence-based medicine in light of limitations in the medical genetics literature, which may mean recommending prophylactic surgery. Also discussed are three BRCA1/2 genetic testing scenarios which illustrate the difficulty of knowing where to "draw the line", i.e., when to offer testing and what level of testing to pursue. Decision-making about BRCA1/2 gene testing including Ashkenazi Jewish founder mutation testing, comprehensive reflex testing, and expedited testing, is explored. The duty to recontact as standard of care evolves requires that medical geneticists determine how to prospectively set expectations with patients as well as to decide which situations require recontact and to determine how to systematically do so. The case of patient recontact regarding new mutation detection techniques with improved sensitivity, e.g., BART testing which is based on the ability to detect large BRCA1/2 rearrangements, is discussed. General principles are highlighted so that these specific cases can be extrapolated to other genes and hereditary conditions by medical geneticists, genetic counselors, and others practicing in the field of cancer genetics.
医学遗传学家必须做出鉴别诊断,践行循证医学,并在临床环境中应用伦理、法律和社会问题(ELSI)原则。本文介绍了几种临床案例,阐述了癌症遗传学领域的困境。这些案例包括乳腺癌和胃癌的鉴别诊断,以及鉴于医学遗传学文献的局限性而在践行循证医学时所面临的困境,这可能意味着推荐预防性手术。文中还讨论了三种BRCA1/2基因检测案例,这些案例说明了确定“界限”的困难,即何时提供检测以及进行何种程度的检测。探讨了关于BRCA1/2基因检测的决策,包括阿什肯纳兹犹太人群体始祖突变检测、全面反射检测和快速检测。随着作为医疗标准的再次联系义务的发展,医学遗传学家需要确定如何前瞻性地为患者设定期望,以及决定哪些情况需要再次联系并确定如何系统地进行。文中讨论了与患者再次联系以告知新的具有更高灵敏度的突变检测技术的情况,例如基于检测BRCA1/2大片段重排能力的BART检测。文中强调了一般原则,以便医学遗传学家、遗传咨询师以及癌症遗传学领域的其他从业者能够将这些具体案例推广到其他基因和遗传性疾病。